A Randomized Trial of Liposomal Paclitaxel plus Cisplatin as First-line Therapy for Advanced Non-small Cell Lung Cancer

A Randomized Trial of Liposomal Paclitaxel plus Cisplatin as First-line Therapy for Advanced Non-small Cell Lung Cancer

Background and objective Paclitaxel plus cisplatin (TP) is used as the standard regimen for patients with advanced non-small cell lung cancer (NSCLC). In this study, we compared the response rate (RR), overall survival (OS), and toxicity of the combined chemotherapy regimen of liposomal paclitaxel p...

Full description

Bibliographic Details
Main Authors: Xi LI, Jinghui WANG, Jingying NONG, Hui ZHANG, Xinjie YANG, Quan ZHANG, Qunhui WANG, Yuan GAO, Shucai ZHANG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2012-04-01
Series:Chinese Journal of Lung Cancer
Subjects:
Liposome
Paclitaxel
Lung neoplasms
Clinical trial
Chemotherapy
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2012.04.03

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2012.04.03

Similar Items